JP2011530295A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011530295A5 JP2011530295A5 JP2011522301A JP2011522301A JP2011530295A5 JP 2011530295 A5 JP2011530295 A5 JP 2011530295A5 JP 2011522301 A JP2011522301 A JP 2011522301A JP 2011522301 A JP2011522301 A JP 2011522301A JP 2011530295 A5 JP2011530295 A5 JP 2011530295A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- norovirus
- amino acid
- particle
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241001263478 Norovirus Species 0.000 claims description 33
- 238000009472 formulation Methods 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 23
- 229920001184 polypeptide Polymers 0.000 claims description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 18
- 239000002131 composite material Substances 0.000 claims description 15
- 230000003053 immunization Effects 0.000 claims description 4
- 238000002649 immunization Methods 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims 42
- 108090000623 proteins and genes Proteins 0.000 claims 25
- 229960005486 vaccine Drugs 0.000 claims 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims 19
- 244000309711 non-enveloped viruses Species 0.000 claims 16
- 150000001413 amino acids Chemical class 0.000 claims 15
- 108091035707 Consensus sequence Proteins 0.000 claims 13
- 108090000565 Capsid Proteins Proteins 0.000 claims 12
- 102100023321 Ceruloplasmin Human genes 0.000 claims 12
- 210000000234 capsid Anatomy 0.000 claims 10
- 238000000034 method Methods 0.000 claims 9
- 229920001282 polysaccharide Polymers 0.000 claims 6
- 239000000843 powder Substances 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 241000369757 Sapovirus Species 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 239000005017 polysaccharide Substances 0.000 claims 4
- 150000004804 polysaccharides Chemical class 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 229920001661 Chitosan Polymers 0.000 claims 3
- 229920002683 Glycosaminoglycan Polymers 0.000 claims 3
- 239000001913 cellulose Substances 0.000 claims 3
- 229920002678 cellulose Polymers 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000003232 mucoadhesive effect Effects 0.000 claims 3
- 208000006339 Caliciviridae Infections Diseases 0.000 claims 2
- 241000724675 Hepatitis E virus Species 0.000 claims 2
- 241001631646 Papillomaviridae Species 0.000 claims 2
- 241000709664 Picornaviridae Species 0.000 claims 2
- 241001505332 Polyomavirus sp. Species 0.000 claims 2
- 241000125945 Protoparvovirus Species 0.000 claims 2
- 241000702263 Reovirus sp. Species 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 230000000890 antigenic effect Effects 0.000 claims 2
- 244000309743 astrovirus Species 0.000 claims 2
- 230000009260 cross reactivity Effects 0.000 claims 2
- 239000002158 endotoxin Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 claims 2
- 229920006008 lipopolysaccharide Polymers 0.000 claims 2
- 239000011859 microparticle Substances 0.000 claims 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims 2
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 claims 2
- 229940097496 nasal spray Drugs 0.000 claims 2
- 239000007922 nasal spray Substances 0.000 claims 2
- 241000701161 unidentified adenovirus Species 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 claims 1
- 241001116389 Aloe Species 0.000 claims 1
- 239000004382 Amylase Substances 0.000 claims 1
- 102000013142 Amylases Human genes 0.000 claims 1
- 108010065511 Amylases Proteins 0.000 claims 1
- 229920000945 Amylopectin Polymers 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 241000407176 Chiba virus Species 0.000 claims 1
- 229920002101 Chitin Polymers 0.000 claims 1
- 229920002567 Chondroitin Polymers 0.000 claims 1
- 229920001287 Chondroitin sulfate Polymers 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 102000053602 DNA Human genes 0.000 claims 1
- 229920000045 Dermatan sulfate Polymers 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- 239000004375 Dextrin Substances 0.000 claims 1
- 229920001353 Dextrin Polymers 0.000 claims 1
- 229920002527 Glycogen Polymers 0.000 claims 1
- 229920002971 Heparan sulfate Polymers 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- 229920001202 Inulin Polymers 0.000 claims 1
- 229920000288 Keratan sulfate Polymers 0.000 claims 1
- 108090001090 Lectins Proteins 0.000 claims 1
- 102000004856 Lectins Human genes 0.000 claims 1
- 241000714209 Norwalk virus Species 0.000 claims 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- 229920002125 Sokalan® Polymers 0.000 claims 1
- 241000714208 Southampton virus Species 0.000 claims 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims 1
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 229920001284 acidic polysaccharide Polymers 0.000 claims 1
- 150000004805 acidic polysaccharides Chemical class 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims 1
- 235000019418 amylase Nutrition 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 claims 1
- 229940059329 chondroitin sulfate Drugs 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 229940124447 delivery agent Drugs 0.000 claims 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 claims 1
- 229940051593 dermatan sulfate Drugs 0.000 claims 1
- 235000019425 dextrin Nutrition 0.000 claims 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 108091008053 gene clusters Proteins 0.000 claims 1
- 229940096919 glycogen Drugs 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229940029339 inulin Drugs 0.000 claims 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims 1
- 229920000831 ionic polymer Polymers 0.000 claims 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 claims 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims 1
- 239000002523 lectin Substances 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 239000012669 liquid formulation Substances 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 239000007764 o/w emulsion Substances 0.000 claims 1
- 239000001814 pectin Substances 0.000 claims 1
- 229920001277 pectin Polymers 0.000 claims 1
- 235000010987 pectin Nutrition 0.000 claims 1
- 229960000292 pectin Drugs 0.000 claims 1
- 229960000502 poloxamer Drugs 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229920002627 poly(phosphazenes) Polymers 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229930182490 saponin Natural products 0.000 claims 1
- 150000007949 saponins Chemical class 0.000 claims 1
- 235000017709 saponins Nutrition 0.000 claims 1
- 229940031439 squalene Drugs 0.000 claims 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 239000000277 virosome Substances 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8750408P | 2008-08-08 | 2008-08-08 | |
| US61/087,504 | 2008-08-08 | ||
| US21860309P | 2009-06-19 | 2009-06-19 | |
| US61/218,603 | 2009-06-19 | ||
| PCT/US2009/053249 WO2010017542A1 (en) | 2008-08-08 | 2009-08-10 | Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015075955A Division JP6448445B2 (ja) | 2008-08-08 | 2015-04-02 | 交差反応性の増強のための複合カプシドアミノ酸配列を含むウイルス様粒子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011530295A JP2011530295A (ja) | 2011-12-22 |
| JP2011530295A5 true JP2011530295A5 (cg-RX-API-DMAC7.html) | 2014-07-10 |
| JP5852883B2 JP5852883B2 (ja) | 2016-02-03 |
Family
ID=41664003
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011522301A Active JP5852883B2 (ja) | 2008-08-08 | 2009-08-10 | 交差反応性の増強のための複合カプシドアミノ酸配列を含むウイルス様粒子 |
| JP2015075955A Active JP6448445B2 (ja) | 2008-08-08 | 2015-04-02 | 交差反応性の増強のための複合カプシドアミノ酸配列を含むウイルス様粒子 |
| JP2017096499A Pending JP2017153484A (ja) | 2008-08-08 | 2017-05-15 | 交差反応性の増強のための複合カプシドアミノ酸配列を含むウイルス様粒子 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015075955A Active JP6448445B2 (ja) | 2008-08-08 | 2015-04-02 | 交差反応性の増強のための複合カプシドアミノ酸配列を含むウイルス様粒子 |
| JP2017096499A Pending JP2017153484A (ja) | 2008-08-08 | 2017-05-15 | 交差反応性の増強のための複合カプシドアミノ酸配列を含むウイルス様粒子 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8841120B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2324113B8 (cg-RX-API-DMAC7.html) |
| JP (3) | JP5852883B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102118458B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN104911154A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009279456B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2733589C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2324113T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2668836T3 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1215051A1 (cg-RX-API-DMAC7.html) |
| NO (1) | NO2324113T3 (cg-RX-API-DMAC7.html) |
| PL (1) | PL2324113T3 (cg-RX-API-DMAC7.html) |
| SG (1) | SG2013057732A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010017542A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2659275C (en) * | 2006-07-27 | 2017-01-10 | Ligocyte Pharmaceuticals, Inc. | Chimeric influenza virus-like particles |
| AU2007303608B2 (en) | 2006-09-29 | 2013-05-02 | Takeda Vaccines, Inc. | Norovirus vaccine formulations |
| WO2008113011A2 (en) | 2007-03-14 | 2008-09-18 | Ligocyte Pharmaceuticals, Inc. | Virus like particle purification |
| US20100266636A1 (en) | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
| US10130696B2 (en) | 2007-09-18 | 2018-11-20 | Takeda Vaccines, Inc. | Method of conferring a protective immune response to norovirus |
| SG2013057732A (en) | 2008-08-08 | 2015-02-27 | Ligocyte Pharmaceuticals Inc | Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity |
| US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
| US20130171185A1 (en) | 2010-07-06 | 2013-07-04 | Ethan Settembre | Norovirus derived immunogenic compositions and methods |
| EA202090699A3 (ru) * | 2011-07-11 | 2020-11-30 | Такеда Вэксинс, Инк. | Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения |
| EP2747778B1 (en) | 2011-08-26 | 2017-12-06 | Wisconsin Alumni Research Foundation | Influenza viruses with mutant pb2 gene segment as live attenuated vaccines |
| JP6567824B2 (ja) * | 2011-10-12 | 2019-08-28 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | ヒトパピローマウイルスのワクチンおよびその使用方法 |
| JOP20130186B1 (ar) | 2012-06-22 | 2021-08-17 | Takeda Vaccines Montana Inc | تنقية الجزيئات الشبيهة بالفيروسات |
| AU2014248535B2 (en) | 2013-03-12 | 2017-03-30 | Inovio Pharmaceuticals, Inc. | Improved vaccines for human papilloma virus and methods for using the same |
| JP6479305B2 (ja) | 2013-07-12 | 2019-03-06 | 株式会社Ｕｍｎファーマ | ウイルス様粒子の精製方法 |
| JP2015015931A (ja) | 2013-07-12 | 2015-01-29 | 株式会社Ｕｍｎファーマ | ウイルス様粒子を含む培養物の製造方法 |
| US10524493B2 (en) * | 2013-09-16 | 2020-01-07 | The Johns Hopkins University | Compositions and methods for preventing or relieving symptoms of infections |
| US10501500B2 (en) | 2013-10-03 | 2019-12-10 | Takeda Vaccines, Inc. | Methods of detection and removal of rhabdoviruses from cell lines |
| KR20230122181A (ko) | 2013-11-29 | 2023-08-22 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 중동 호흡기 증후군 코로나바이러스(MERS-CoV) 백신 |
| US10053671B2 (en) | 2014-06-20 | 2018-08-21 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
| MX2018002419A (es) | 2015-08-28 | 2018-11-29 | Ology Bioservices Inc | Vacuna de norovirus. |
| EP3341018A1 (en) * | 2015-08-28 | 2018-07-04 | Wisconsin Alumni Research Foundation | Generation of infectious influenza viruses from virus-like particles |
| EP3385274B1 (en) * | 2015-12-04 | 2021-09-22 | Xiamen University | Mutant of human papillomavirus type 11 l1 protein |
| US11197925B2 (en) | 2016-02-19 | 2021-12-14 | Wisconsin Alumni Research Foundation (Warf) | Influenza B virus replication for vaccine development |
| BR112018074853A2 (pt) * | 2016-06-03 | 2019-04-02 | Quest Diagnostics Investments Llc | métodos para detectar a presença de pelo menos um genogrupo de norovírus em uma amostra de fezes e para selecionar um paciente que sofre de gastroenterite aguda, e, kit |
| CA3056812C (en) * | 2017-03-23 | 2022-11-29 | Medicago Inc. | Norovirus fusion proteins and vlps comprising norovirus fusion proteins |
| TWI743346B (zh) | 2017-03-31 | 2021-10-21 | 國立大學法人東京大學 | 諾羅病毒抗體 |
| JP6795468B2 (ja) * | 2017-07-14 | 2020-12-02 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | ヒトパピローマウイルスのワクチンおよびその使用方法 |
| WO2019079594A1 (en) * | 2017-10-18 | 2019-04-25 | The University Of North Carolina At Chapel Hill | METHODS AND COMPOSITIONS FOR VACCINES AGAINST NOVOVIRUS AND DIAGNOSIS OF NOVOVIRUS |
| US11197926B2 (en) | 2017-10-25 | 2021-12-14 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized HA for replication in eggs |
| CN109776657B (zh) * | 2017-11-14 | 2021-11-26 | 北京康乐卫士生物技术股份有限公司 | 重组诺如病毒vlp颗粒和制备方法及其用途 |
| PH12020550732A1 (en) * | 2017-11-30 | 2021-04-19 | Medicago Inc | Modified norovirus vp1 proteins and vlps comprising modified norovirus vp1 proteins |
| CA3083953A1 (en) * | 2017-12-11 | 2019-06-20 | Board Of Regents, The University Of Texas System | Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration |
| JP7651127B2 (ja) * | 2018-06-04 | 2025-03-26 | 厦▲門▼大学 | ヒトパピローマウイルス３９型のｌ１タンパク質の変異体 |
| KR102075393B1 (ko) * | 2018-06-28 | 2020-02-11 | 한국과학기술원 | 중증 열성 혈소판 감소 증후군(sfts) 바이러스 감염 질환 예방 또는 치료용 백신 조성물 |
| EP3821014A4 (en) | 2018-07-13 | 2022-04-20 | Medicago Inc. | Modified norovirus vp1 proteins and vlps comprising modified norovirus vp1 proteins |
| WO2020033527A2 (en) | 2018-08-07 | 2020-02-13 | Wisconsin Alumni Research Foundation (Warf) | Recombinant biologically contained filovirus vaccine |
| WO2020041311A1 (en) | 2018-08-20 | 2020-02-27 | Wisconsin Alumni Research Foundation | Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (ha) protein |
| EP3840778A1 (en) | 2018-08-20 | 2021-06-30 | Takeda Vaccines, Inc. | Vlp formulations |
| AR117462A1 (es) * | 2018-12-20 | 2021-08-04 | Takeda Vaccines Inc | Vacuna contra norovirus, formulaciones y métodos |
| EP3921413A1 (en) | 2019-02-08 | 2021-12-15 | Wisconsin Alumni Research Foundation (WARF) | Humanized cell line |
| WO2020223699A1 (en) | 2019-05-01 | 2020-11-05 | Wisconsin Alumni Research Foundation (Warf) | Improved influenza virus replication for vaccine development |
| WO2021041624A2 (en) | 2019-08-27 | 2021-03-04 | Yoshihiro Kawaoka | Recombinant influenza viruses with stabilized ha for replication in eggs |
| JP7075130B2 (ja) * | 2019-10-25 | 2022-05-25 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | ヒトパピローマウイルスのワクチンおよびその使用方法 |
| WO2021150874A1 (en) | 2020-01-24 | 2021-07-29 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized na |
| US12290562B2 (en) | 2020-03-25 | 2025-05-06 | Wisconsin Alumni Research Foundation (Warf) | Recombinant multivalent influenza viruses |
| CN114316033A (zh) * | 2020-09-29 | 2022-04-12 | 香港理工大学深圳研究院 | 一种特异性识别诺如病毒的单克隆抗体及制备方法与应用 |
| EP4273155A4 (en) * | 2020-12-30 | 2025-03-12 | Grand Theravac Life Science (Nanjing) Co., Ltd. | NOROVIRUS VIRUS-LIKE PARTICLE, IMMUNE COMPOSITION OR KIT AND USE THEREOF |
| JPWO2022244860A1 (cg-RX-API-DMAC7.html) * | 2021-05-20 | 2022-11-24 | ||
| WO2022246323A1 (en) | 2021-05-21 | 2022-11-24 | Takeda Vaccines, Inc. | Solid composition, freeze-drying method and glass vial |
| WO2023060086A1 (en) | 2021-10-04 | 2023-04-13 | Takeda Vaccines, Inc. | Methods for determining norovirus-reactive antibodies |
| WO2023183458A1 (en) * | 2022-03-25 | 2023-09-28 | Merck Sharp & Dohme Llc | Controlled release vaccine formulations |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6572862B1 (en) | 1989-11-08 | 2003-06-03 | Baylor College Of Medicine | Methods and reagents to detect and characterize Norwalk and related viruses |
| WO1992016543A1 (en) | 1991-03-25 | 1992-10-01 | Genelabs Incorporated | NORWALK VIRUS HUMAN GASTROENTERITIS AGENT AND MOLECULAR CLONING OF CORRESPONDING cDNAs |
| JPH07509122A (ja) * | 1992-04-08 | 1995-10-12 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ，アズ レプリゼンテッド バイ ザ セクレター，デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 野生型麻疹ウイルス糖タンパク質：ワクチンおよびその検出方法 |
| WO1994005700A2 (en) | 1992-09-07 | 1994-03-17 | Baylor College Of Medicine | Methods and reagents to detect and characterize norwalk and related viruses |
| US5788970A (en) * | 1994-03-29 | 1998-08-04 | The University Of Maryland College Park | Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon |
| PL183781B1 (pl) * | 1994-05-16 | 2002-07-31 | Merck & Co Inc | Sposób wytwarzania szczepionki przeciwko ludzkiemu wirusowi brodawczaków |
| US5645051A (en) * | 1995-04-21 | 1997-07-08 | Dura Pharmaceuticals, Inc. | Unit dose dry powder inhaler |
| US5861241A (en) * | 1995-08-16 | 1999-01-19 | University Of Massachusetts | Monoclonal antibodies for detecting Norwalk virus |
| GB9525083D0 (en) * | 1995-12-07 | 1996-02-07 | Danbiosyst Uk | Vaccine compositions |
| US5953727A (en) * | 1996-10-10 | 1999-09-14 | Incyte Pharmaceuticals, Inc. | Project-based full-length biomolecular sequence database |
| US6491919B2 (en) * | 1997-04-01 | 2002-12-10 | Corixa Corporation | Aqueous immunologic adjuvant compostions of monophosphoryl lipid A |
| CA2288129A1 (en) * | 1997-05-01 | 1998-11-12 | Chiron Corporation | Use of virus-like particles as adjuvants |
| US20040265377A1 (en) * | 1997-10-27 | 2004-12-30 | Harry Seager | Solid dispersing vaccine composition for oral delivery |
| ATE324436T1 (de) * | 1998-08-14 | 2006-05-15 | Merck & Co Inc | Verfahren zur reinigung von menschlichen, dem papillomavirus ähnlichen partikeln. |
| ES2262359T3 (es) | 1998-12-17 | 2006-11-16 | MERCK & CO., INC. | Particulas tipo virus sinteticas con epitores heterologos. |
| WO2000079280A1 (en) | 1999-06-22 | 2000-12-28 | Japan As Represented By Director-General National Institute Of Infectious Diseases | Srsv detection kit |
| JP2002020399A (ja) | 2000-07-10 | 2002-01-23 | Osaka Prefecture | ノルウォークウイルス（ｎｖ）を認識するモノクローナル抗体 |
| WO2003068933A2 (en) * | 2002-02-14 | 2003-08-21 | Novavax, Inc. | Optimization of gene sequences of virus-like particles for expression in insect cells |
| EP1513552B1 (en) * | 2002-06-20 | 2010-12-01 | Cytos Biotechnology AG | Packaged virus-like particles in combination with cpg for use as adjuvants with allergens : method of preparation and use |
| US7879338B2 (en) * | 2003-07-21 | 2011-02-01 | Boyce Thompson Institute For Plant Research | Vectors and methods for immunization against norovirus using transgenic plants |
| EP1670824A2 (en) | 2003-09-24 | 2006-06-21 | Montana State University | Norovirus monoclonal antibodies and peptides |
| WO2005037223A2 (en) * | 2003-10-15 | 2005-04-28 | Brigham And Women's Hospital, Inc. | Methods and compositions for immunomodulation |
| US20050215501A1 (en) * | 2003-10-24 | 2005-09-29 | Coley Pharmaceutical Group, Inc. | Methods and products for enhancing epitope spreading |
| FR2863890B1 (fr) | 2003-12-19 | 2006-03-24 | Aventis Pasteur | Composition immunostimulante |
| US7481997B1 (en) * | 2004-02-12 | 2009-01-27 | Montana State University | Snow mountain virus genome sequence, virus-like particles and methods of use |
| US20050260225A1 (en) * | 2004-05-18 | 2005-11-24 | Goldberg Joanna B | Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens |
| CU23496A1 (es) * | 2004-09-03 | 2010-02-23 | Ct Ingenieria Genetica Biotech | Composición vacunal contra el virus de la hepatitis c |
| US8029802B2 (en) | 2004-10-20 | 2011-10-04 | Sanofi Pasteur Biologics Co. | Vaccines against Japanese encephalitis virus and West Nile virus |
| GB0428394D0 (en) | 2004-12-24 | 2005-02-02 | Chiron Srl | Saccharide conjugate vaccines |
| US8168771B2 (en) * | 2005-01-31 | 2012-05-01 | The Johns Hopkins University | Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants |
| NZ599345A (en) | 2005-02-18 | 2013-07-26 | Novartis Vaccines & Diagnostic | Immunogens from uropathogenic Escherichia Coli |
| CN101141979B (zh) | 2005-03-18 | 2013-05-08 | 赛托斯生物技术公司 | 猫变应原融合蛋白及其用途 |
| EP1736538A1 (en) | 2005-06-21 | 2006-12-27 | Cytos Biotechnology AG | Process for the preparative purification of virus-like-particles (VLPs) |
| JP4825958B2 (ja) * | 2005-08-10 | 2011-11-30 | 財団法人ヒューマンサイエンス振興財団 | 高リスク群ヒトパピローマウイルスの中和抗体を誘導する抗原 |
| JP5215865B2 (ja) | 2005-11-22 | 2013-06-19 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド | ノロウイルス抗原およびサポウイルス抗原 |
| JP2007145775A (ja) * | 2005-11-29 | 2007-06-14 | Falco Life Science:Kk | ノロウイルスｇｉの高感度検出方法 |
| AU2007303608B2 (en) * | 2006-09-29 | 2013-05-02 | Takeda Vaccines, Inc. | Norovirus vaccine formulations |
| US20100266636A1 (en) * | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
| US10130696B2 (en) * | 2007-09-18 | 2018-11-20 | Takeda Vaccines, Inc. | Method of conferring a protective immune response to norovirus |
| SG2013057732A (en) | 2008-08-08 | 2015-02-27 | Ligocyte Pharmaceuticals Inc | Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity |
| US8980275B2 (en) * | 2010-01-21 | 2015-03-17 | Takeda Vaccines, Inc. | Targeted heterologous antigen presentation on calicivirus virus-like particles |
-
2009
- 2009-08-10 SG SG2013057732A patent/SG2013057732A/en unknown
- 2009-08-10 AU AU2009279456A patent/AU2009279456B2/en active Active
- 2009-08-10 WO PCT/US2009/053249 patent/WO2010017542A1/en not_active Ceased
- 2009-08-10 CA CA2733589A patent/CA2733589C/en active Active
- 2009-08-10 NO NO09805653A patent/NO2324113T3/no unknown
- 2009-08-10 PL PL09805653T patent/PL2324113T3/pl unknown
- 2009-08-10 DK DK09805653.4T patent/DK2324113T3/en active
- 2009-08-10 KR KR1020177030841A patent/KR102118458B1/ko active Active
- 2009-08-10 CN CN201510127943.5A patent/CN104911154A/zh active Pending
- 2009-08-10 EP EP09805653.4A patent/EP2324113B8/en active Active
- 2009-08-10 KR KR1020117005478A patent/KR101793161B1/ko active Active
- 2009-08-10 ES ES09805653.4T patent/ES2668836T3/es active Active
- 2009-08-10 CN CN200980139886.5A patent/CN102177233B/zh active Active
- 2009-08-10 EP EP18158843.5A patent/EP3382011A1/en active Pending
- 2009-08-10 JP JP2011522301A patent/JP5852883B2/ja active Active
-
2011
- 2011-02-08 US US13/023,363 patent/US8841120B2/en active Active
-
2014
- 2014-07-25 US US14/341,375 patent/US9518096B2/en active Active
-
2015
- 2015-04-02 JP JP2015075955A patent/JP6448445B2/ja active Active
-
2016
- 2016-03-16 HK HK16103047.9A patent/HK1215051A1/zh unknown
-
2017
- 2017-05-15 JP JP2017096499A patent/JP2017153484A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011530295A5 (cg-RX-API-DMAC7.html) | ||
| JP6448445B2 (ja) | 交差反応性の増強のための複合カプシドアミノ酸配列を含むウイルス様粒子 | |
| AU2011207355B2 (en) | Targeted heterologous antigen presentation on Calicivirus virus-like particles | |
| JP2016020378A5 (cg-RX-API-DMAC7.html) | ||
| JP2010539192A5 (cg-RX-API-DMAC7.html) | ||
| US20220054621A1 (en) | Norovirus vaccine formulations and methods | |
| JP5735121B2 (ja) | インフルエンザウィルスの組換えヘマグルチニン蛋白質及びそれを含むワクチン | |
| CA2923040A1 (en) | Mucosal vaccine composition | |
| JP2023128573A (ja) | 腸管へのウイルス特異的な抗体誘導が可能なノロウイルスワクチン | |
| HK1156070B (en) | Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity | |
| HK1156070A (en) | Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity |